Cargando…

Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review

BACKGROUND: Osteosarcoma is the most common bone tumor in children and adolescents. Despite multiagent chemotherapy, only 71% of patients survives and these survivors often experience long-term toxicities. The main objective of this systematic review is to provide an overview of the discovery of nov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurkmans, Evelien G. E., Brand, Annouk C. A. M., Verdonschot, Job A. J., te Loo, D. Maroeska W. M., Coenen, Marieke J. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761983/ https://www.ncbi.nlm.nih.gov/pubmed/36536332 http://dx.doi.org/10.1186/s12885-022-10434-5

Ejemplares similares

Analysis of Drug Metabolizing Gene Panel in Osteosarcoma Patients Identifies Association Between Variants in SULT1E1, CYP2B6 and CYP4F8 and Methotrexate Levels and Toxicities
por: Hurkmans, Evelien G. E., et al.
Publicado: (2020)

Survival Trends and Long-Term Toxicity in Pediatric Patients with Osteosarcoma
por: Hagleitner, Melanie M., et al.
Publicado: (2012)

Contribution of common and rare genetic variants in CEP72 on vincristine‐induced peripheral neuropathy in brain tumour patients
por: Klumpers, Marije J., et al.
Publicado: (2022)

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2018)

Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic Study
por: Caronia, Daniela, et al.
Publicado: (2011)

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact
por: Hattinger, Claudia Maria, et al.
Publicado: (2020)

Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma
por: Hegyi, Marta, et al.
Publicado: (2016)

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
por: Bray, J, et al.
Publicado: (2010)

SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin
por: Hurkmans, Evelien G. E., et al.
Publicado: (2022)

Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy
por: Urtasun, Andrea, et al.
Publicado: (2023)

Pharmacogenetics of the Primary and Metastatic Osteosarcoma: Gene Expression Profile Associated with Outcome
por: Trujillo-Paolillo, Alini, et al.
Publicado: (2023)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature
por: Berm, Elizabeth J. J., et al.
Publicado: (2016)

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients
por: Hecker-Nolting, Stefanie, et al.
Publicado: (2021)

Role of Drug–Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity
por: Jessurun, Naomi T., et al.
Publicado: (2021)

Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome.
por: Ladona, M G, et al.
Publicado: (2001)

Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans
por: Mateza, Somila, et al.
Publicado: (2023)

Chemotherapy for osteosarcoma.
por: Souhami, R. L.
Publicado: (1989)

Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy
por: Huang, Chien-Yu, et al.
Publicado: (2019)

Systematic Review of Pharmacogenetic Warfarin Dosing
por: van Schie, Rianne M. F., et al.
Publicado: (2009)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

Pharmacogenetics of FAC chemotherapy side effects in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2015)

Pharmacogenetics in the clinic
por: Guchelaar, H.-J.
Publicado: (2013)

Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
por: McTiernan, Anne, et al.
Publicado: (2012)

Experimental Pharmacogenetics
por: Lubs, Herbert A.
Publicado: (1964)

Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study)
por: Driessen, Chantal M., et al.
Publicado: (2019)

Influence of Genetic Variants in TPMT and COMT Associated with Cisplatin Induced Hearing Loss in Patients with Cancer: Two New Cohorts and a Meta-Analysis Reveal Significant Heterogeneity between Cohorts
por: Hagleitner, Melanie M., et al.
Publicado: (2014)

An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity
por: Alzghari, Saeed K
Publicado: (2018)

Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
por: Cheng, Lin
Publicado: (2021)

Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review
por: Morris, Sarah A., et al.
Publicado: (2022)

The Pharmacogenetics of Type 2 Diabetes: A Systematic Review
por: Maruthur, Nisa M., et al.
Publicado: (2014)

Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis
por: Bek, S, et al.
Publicado: (2017)

Race and Drug Toxicity: A Study of Three Cardiovascular Drugs with Strong Pharmacogenetic Recommendations
por: O’Brien, Travis J., et al.
Publicado: (2021)

Pharmacogenetic information in Swiss drug labels – a systematic analysis
por: Jeiziner, C., et al.
Publicado: (2020)

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

Pharmacogenetic testing in the Veterans Health Administration: Policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee
por: Vassy, Jason L., et al.
Publicado: (2018)

Pharmacogenetics of Antiplatelet Drugs
por: Curtin, Ronan, et al.
Publicado: (2002)

Pharmacogenetics of lipid diseases
por: Ordovas, Jose M
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_ifl8oms0m7pu5au8obdumaac76